Gynecologic Oncology Group

61 total trials 29 currently recruiting 30 completed

Trial Pipeline

RECRUITING

Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer

NCT01000259

ACTIVE NOT RECRUITING Phase 2

Abemaciclib and Letrozole to Treat Endometrial Cancer

NCT04393285

ACTIVE NOT RECRUITING Phase 2

Ribociclib and Letrozole Treatment in Ovarian Cancer

NCT03673124

COMPLETED Phase 2

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

NCT01225887

COMPLETED Phase 2

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT01267253

COMPLETED

Prognostic Biomarkers in Patients With Endometrial Cancer

NCT01208467

COMPLETED

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer

NCT01139957

COMPLETED

Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer

NCT01198171

COMPLETED

Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

NCT01164735

COMPLETED

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

NCT01344837

COMPLETED Phase 2

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00939809

COMPLETED Phase 2

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

NCT00309959

COMPLETED Phase 2

Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia

NCT00081263

COMPLETED Phase 2

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

NCT00031629

COMPLETED Phase 1

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

NCT00104910

COMPLETED Phase 2

Pemetrexed Disodium in Treating Patients With Recurrent Cancer of the Cervix

NCT00087113

COMPLETED Phase 2

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

NCT00064025

COMPLETED Phase 2

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

NCT00101127

COMPLETED

Vaginal Changes and Sexual Function in Patients With Cervical Cancer

NCT00053261

COMPLETED NA

EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer

NCT00049231

COMPLETED Phase 2

Irofulven in Treating Patients With Persistent or Recurrent, Refractory Endometrial Cancer

NCT00005031

COMPLETED Phase 1

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

NCT00005026

COMPLETED Phase 3

Lymphatic Mapping in Treating Patients With Stage I or Stage II Cancer of the Vulva

NCT00003325

COMPLETED Phase 1

Radiation Therapy, Paclitaxel, and Cisplatin in Treating Patients With Cancer of the Cervix

NCT00003377

COMPLETED Phase 1

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003967

COMPLETED Phase 3

Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer

NCT00003644

COMPLETED NA

Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer

NCT00003384

COMPLETED Phase 3

Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix

NCT00003078

COMPLETED Phase 3

Surgery With or Without Chemotherapy in Treating Patients With Stage IB Cervical Cancer

NCT00002536

COMPLETED Phase 3

Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

NCT00002717

COMPLETED Phase 3

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Cancer of the Uterus

NCT00002546

COMPLETED Phase 2

Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers

NCT00002538

COMPLETED Phase 3

Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer

NCT00002493

What the Pipeline for Gynecologic Oncology Group Shows

According to the ClinicalTrials.gov registry, Gynecologic Oncology Group is linked to 61 US clinical trials across every stage of research activity. Of those, 29 studies are currently recruiting — about 48% of the sponsor's indexed portfolio — and 30 are already marked complete, representing roughly 49% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Gynecologic Oncology Group reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 17 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Gynecologic Oncology Group is Cervical Cancer with 6 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial